本文選題：藥品安全　切入點(diǎn)：責(zé)任保險　出處：《遼寧大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：自1978年改革開放以來,不僅我國的經(jīng)濟(jì)發(fā)展取得了快速的進(jìn)步,我國很多事業(yè)也取得了飛快的進(jìn)步,例如我國醫(yī)藥產(chǎn)業(yè)快速發(fā)展,雖然其市場化程度在不斷加深,但這一進(jìn)步對我國國民健康以及其他方面的影響是具有雙面性的。它既有有利的一面,又有不利的一面。好的一面是,正是由于醫(yī)藥行業(yè)的快速發(fā)展,改善了我國人民的生活狀況,人們的生活變的如此快捷與方便,這提高了居民幸福指數(shù)。但不好的一面是,有些心術(shù)不正的人可能利用這一科技,利用藥品來制造麻煩,藥品的安全性越來越被人們所重視。藥品安全對人們來說是至關(guān)重要的,這關(guān)系著每個人的生命,不僅我們自身應(yīng)該予以關(guān)注,政府也應(yīng)該提高對藥品安全重視度。但是,要想真正提升藥品安全,必須提高個人的安全意識,只有落實到每個主體上,才能從根本上解決問題。這不僅要求國家應(yīng)該制定相關(guān)法律來保證實施,同時,這也是我們每個公民的責(zé)任。本文以維護(hù)消費(fèi)者的根本利益為出發(fā)點(diǎn),從方方面面論述我國建立藥品安全責(zé)任保險的必要性與可行性。面對頻繁發(fā)生的藥品安全責(zé)任事故事件,建立藥品安全責(zé)任制度是勢在必行的,制定的原因可以歸納為以下幾種:一是對于一些質(zhì)量不合格的藥品給消費(fèi)者帶來預(yù)期之外的不良反應(yīng)時,生產(chǎn)商是否應(yīng)該承擔(dān)相應(yīng)的責(zé)任問題,如果生產(chǎn)商的確應(yīng)該承擔(dān)責(zé)任時,因藥品服用時間過長已經(jīng)無法找到生產(chǎn)商,這時責(zé)任該由誰負(fù)責(zé);二是藥品因本身固有的危險性的存在,對于藥品質(zhì)量問題的認(rèn)定是很難的,在實務(wù)中認(rèn)定藥品質(zhì)量合格與否的標(biāo)準(zhǔn)更難確定,在這方面的法律法規(guī)仍然很模糊;三是對于一些藥品安全導(dǎo)致的事件,我國應(yīng)該建立藥品安全責(zé)任強(qiáng)制保險來避免事故發(fā)生后的糾紛問題,但是現(xiàn)有的法律仍然沒有相關(guān)規(guī)定。本文運(yùn)用多種方法相結(jié)合來研究藥品安全責(zé)任保險相關(guān)問題,在此基礎(chǔ)上,提出對策建議以推進(jìn)藥品安全強(qiáng)制責(zé)任保險的推出。
[Abstract]:Since the reform and opening up in 1978, not only has China made rapid progress in economic development, but also many undertakings in China have made rapid progress, such as the rapid development of the pharmaceutical industry in our country, although the degree of marketization is deepening. But this progress has a dual impact on our national health and other aspects. It has both advantages and disadvantages. The good side is that it is precisely because of the rapid development of the pharmaceutical industry, It has improved the living conditions of our people, and people's lives have become so fast and convenient, which has increased the happiness index of the residents. But the bad side is that some people with bad intentions may take advantage of this technology and use drugs to create trouble. People pay more and more attention to the safety of drugs. Drug safety is very important to people, which is related to the lives of everyone. Not only should we pay attention to it, but the government should also pay more attention to the safety of drugs. However, In order to really enhance drug safety, we must raise the personal safety awareness. Only by implementing it to each subject can we solve the problem fundamentally. This not only requires the state to formulate relevant laws to ensure implementation, but also, at the same time, This is also the responsibility of each of our citizens. This paper, based on the fundamental interests of consumers, discusses the necessity and feasibility of establishing drug safety liability insurance in China from all aspects. In the face of frequent incidents of drug safety liability accidents, It is imperative to establish a drug safety liability system. The reasons for the establishment can be summarized as follows: first, when some unqualified drugs bring unexpected adverse reactions to consumers, Whether the manufacturer should bear the corresponding responsibility, if the manufacturer should take the responsibility, the manufacturer can not find the manufacturer because the drug is used for too long, then who should be responsible for the responsibility; Second, because of the inherent danger of drugs, it is very difficult to identify the quality of drugs, and it is more difficult to determine the standards of drug quality in practice, and the laws and regulations in this respect are still very vague; Third, for some incidents caused by drug safety, China should establish compulsory drug safety liability insurance to avoid disputes after the accident. However, there are still no relevant provisions in the existing laws. This paper uses a variety of methods to study the related issues of drug safety liability insurance, and puts forward countermeasures and suggestions to promote the introduction of compulsory liability insurance for drug safety.
【學(xué)位授予單位】：遼寧大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：F426.72;F842.6

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳杰;趙桂芹;;我國非壽險業(yè)承保業(yè)務(wù)間的風(fēng)險分散效應(yīng)研究[J];保險研究;2014年12期

2 李祝用;姚兆中;;再論交強(qiáng)險的制度定位——立法的缺陷、行政法規(guī)與司法解釋的矛盾及其解決[J];保險研究;2014年04期

3 王云蘭;阮俊慧;;地方性法規(guī)、規(guī)章的效力分析——淺析《中華人民共和國立法法》第80條、第82條、第86條[J];經(jīng)濟(jì)研究導(dǎo)刊;2011年30期

4 胡曉;周典;吳丹;張勤;張博;;公立醫(yī)院取消藥品加成利弊分析[J];中國衛(wèi)生事業(yè)管理;2011年01期

5 褚萬里;;我國交強(qiáng)險制度的成功與不足[J];道路交通管理;2010年08期

6 周書美;;論我國藥品費(fèi)用快速增長的原因與控制[J];內(nèi)蒙古財經(jīng)學(xué)院學(xué)報(綜合版);2010年02期

7 田昕;宋雅然;張新平;;以系統(tǒng)理論分析國家基本藥物制度[J];中國衛(wèi)生事業(yè)管理;2010年04期

8 鄭振Oz;;逐步解決公立醫(yī)院“以藥補(bǔ)醫(yī)”的探討[J];衛(wèi)生經(jīng)濟(jì)研究;2010年01期

9 張領(lǐng)偉;羅鳴;;論交強(qiáng)險經(jīng)營模式與道路救助基金職能[J];保險研究;2009年12期

10 吳年冬;;淺談我國產(chǎn)品責(zé)任保險體系的構(gòu)建[J];區(qū)域金融研究;2009年04期

，

本文編號：1565053